NASDAQ:ZEAL - ZEALAND PHARMA/S Stock Price, Forecast & News

ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."

ZEALAND PHARMA/S (NASDAQ:ZEAL) posted its quarterly earnings results on Thursday, November, 14th. The company reported ($0.51) EPS for the quarter, beating the Zacks' consensus estimate of ($0.69) by $0.18. The firm had revenue of $1.48 million for the quarter, compared to analysts' expectations of $7.50 million. View ZEALAND PHARMA/S's Earnings History.

ZEALAND PHARMA/S is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for ZEALAND PHARMA/S.

5 equities research analysts have issued 12 month price objectives for ZEALAND PHARMA/S's shares. Their forecasts range from $38.00 to $42.00. On average, they expect ZEALAND PHARMA/S's stock price to reach $40.33 in the next twelve months. This suggests a possible upside of 11.0% from the stock's current price. View Analyst Price Targets for ZEALAND PHARMA/S.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZEALAND PHARMA/S.

Media headlines about ZEAL stock have been trending very positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZEALAND PHARMA/S earned a news impact score of 3.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for ZEALAND PHARMA/S.

Some companies that are related to ZEALAND PHARMA/S include BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), United Therapeutics (UTHR), Allakos (ALLK), Evotec (EVTCY), Blueprint Medicines (BPMC), FibroGen (FGEN), HUTCHISON CHINA/S (HCM), Mirati Therapeutics (MRTX), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK) and Deciphera Pharmaceuticals (DCPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other ZEALAND PHARMA/S investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), Tandem Diabetes Care (TNDM), Ford Motor (F), Wells Fargo & Co (WFC), NVIDIA (NVDA), Alibaba Group (BABA) and Tesla (TSLA).

(ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZEAL stock can currently be purchased for approximately $36.34.

ZEALAND PHARMA/S has a market capitalization of $1.16 billion and generates $6.02 million in revenue each year. The company earns $92.07 million in net income (profit) each year or $3.00 on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe.View Additional Information About ZEALAND PHARMA/S.

The official website for ZEALAND PHARMA/S is http://www.zealandpharma.com/.

ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]